Who is this relevant for?
- Pharmaceutical buyers sourcing shortage medicines
- Hospitals managing supply risk
Researchers at Mass General Brigham Heart and Vascular Institute have developed an integrated polygenic risk score (PRS) that estimates inherited risk for eight cardiovascular conditions using a single genetic test. The tool combines several risk models into one comprehensive score, targeting coronary artery disease, atrial fibrillation, type 2 diabetes, venous thromboembolism, thoracic aortic aneurysm, extreme hypertension, severe hypercholesterolemia, and elevated lipoprotein(a).
Validation in over 53,000 individuals showed strong discrimination. Those in the top 10% of genetic risk had, for example, 3.7-fold higher odds for coronary artery disease and 4.1-fold higher odds for severe hypercholesterolemia. The tool improves risk classification beyond traditional clinical factors like age, blood pressure, and cholesterol. It generates standardized risk categories and can integrate into electronic health records.
For pharmaceutical buyers and hospitals, the operational implication is clear. Early identification of high-risk individuals could shift treatment patterns. More patients may start preventive therapies earlier, potentially increasing demand for statins, antihypertensives, and anticoagulants. Hospitals may need to adjust supply forecasting and care pathways. The tool is already available through Mass General Brigham Laboratory for Molecular Medicine and Broad Clinical Labs.
The authors note that while PRS performance is consistent across ancestry groups, predictive strength is lower in populations with greater genetic variation from European reference datasets. The framework is designed to update as new data emerges. Broader validation and cost-effectiveness studies are underway.